- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was Dominant
Separate analysis showed Johnson & Johnson COVID-19 vaccine booster generated 41-fold increase in neutralizing antibodies and a 5-fold increase in T-cells against Omicron
FDA Approves Two New Indications for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
XARELTO® is available as both an oral tablet and oral suspension formulation for use in appropriate children less than 18 years of age Convenient oral suspension formulation advances standard of care for children; alleviates administration challenges found with injectable alternatives XARELTO® now has 11 indications, the most of any direct oral anticoagulant (DOAC), and is the only Factor Xa anticoagulant to offer flexible weight-based dosing for pediatric patients
Johnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19 Vaccine
CHMP recommendation based on data showing a booster (second shot) of the Johnson & Johnson COVID-19 vaccine increased protection to 75 percent against symptomatic COVID-19 infection globally Data also demonstrated 100 percent protection against severe COVID-19, at least 14 days post-booster vaccination The Johnson & Johnson COVID-19 vaccine, when given as a booster or primary shot, was generally well-tolerated
New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma
Phase 1b results of teclistamab in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) also presented at ASH 2021 Annual Meeting
Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma
Updated results of weekly and biweekly dosing of talquetamab monotherapy and initial results in combination with daratumumab presented in oral presentations at the ASH 2021 Annual Meeting
New Clinical and Real-World Data Support Use of DARZALEX® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma
Investigational DARZALEX® quadruple combination regimen shows responses in newly diagnosed, transplant-eligible patients in randomized Phase 2 GRIFFIN study Real-world evidence analysis examines the impact of frontline versus second-line treatment with DARZALEX®-based combinations in transplant-ineligible patients
New Data from Phase 3 GLOW Study Show Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrated Deeper and Sustained Undetectable Minimal Residual Disease Outcomes in First-Line Chronic Lymphocytic Leukemia
Updated results from the MRD cohort of the Phase 2 CAPTIVATE study also highlight potential for treatment-free remissions with IMBRUVICA® plus venetoclax in an oral presentation at ASH 2021
World Health Organization Strategic Advisory Group of Experts (SAGE) Interim Recommendation Supports Use of Johnson & Johnson COVID-19 Vaccine as a Booster
Growing body of evidence supports use of the Johnson & Johnson COVID-19 vaccine as both a mix-and-match and homologous booster, following primary vaccination regimen